JohnM

Author Archives

Recent Author Comments

On What's being hinted at as Ray Blanco's "1 Stock for a Life-Changing Marijuana Payday?"
Now a mere $1.46...[...]
On Yastine's "$5 Biotech Stock Revolutionizing Health Care"
Antares' technology can push a viscous drug like Makena through a fine 27-gauge needle in 15 seconds for a painless auto-injection in the back of the upper arm. Compare that to Makena in a doctor's office - a painful 22-gauge intramuscular injection in th[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
Jeffrey - Whether Cleveland buys, owns, or sells ARTH will have no impact on the fundamentals of the company. I am holding ARTH long term for $10 to $12 a share either based on their royalty streams or a buyout. Cleveland's perspective is very welcome here[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
Cleveland - Happy Father's Day! A good day to ignore aholes and trolls, just like the other 364 days a year. Illegitimi non carborundum. The wound care applications for AC5 are huge. Hospitals don't get reimbursed for treating bedsores, a "preventable" pro[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
ARTH completed an offering of $2.8 million on May 13. There is no way another offering is around the corner.[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
Completely agree PLUS I have never heard Norchi so animated and high energy. The partnering talks must be going well, meaning no more capital raises. Relieved of that stress after 10 years, he sounded like he knows he's riding a winning horse. For less th[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
At last, a voice of reason on this thread. As for the 5-bagger, in Steve Martin's "Picasso at the Lapin Agile," Picasso says: "Look at the stars - millions and millions of stars!" And Einstein replies: "You're way too low."[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
ARTH posted a video two or three years ago showing AC5 stopping arterial bleeding in a pig. KSS wrote about it several times.[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
What did you hear in the BIO presentation that made you begin to lose confidence in Norchi?[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
A ton of new stuff. Don't miss it. https://www.veracast.com/webcasts/bio/ceoinvestor2019/33121486228.cfm?db=0.7073717013304248[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
Right here. Norchi is presenting to the Biotech Showcase Tuesday, Jan. 8, at 9 AM PST. Probably new comments after that.[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
Or in January, as Norchi has said.[...]
On Biotech Discussion... continued
$DMCAF np, stocks usually fall pretty sharply after a reverse split, so there may be a very attractive entry point coming up.[...]
On Biotech Discussion... continued
$LPTX np - Good update on their ESMO presentation https://seekingalpha.com/instablog/498952-bret-jensen/5227910-updated-view-leap-therapeutics $CWBR long "The Cell’s Power Plant: Probing mitochondria and oxygen, Vamsi Mootha finds new ways to understand[...]
On IPOs that are "Like Buying Apple in 1981?"
What is your service?[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
It was one of Norchi's best presentations ever. The moderating analyst let him run over and asked several key questions. It's well worth listening to.[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
Norchi once said two to four months, but he has not repeated that recently.[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
Depends on whether it runs up in advance of approval by short-term traders. That often happens in biotech.[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
Not Cleveland, but the Irish trial was not a Phase 2 trial. It was the only trial required for external use registration in both the US and Europe. Norchi has said he will file for 510(k) approval by the end of September and EMA approval in the December qu[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
I think letting changes in the stock price affect your faith in the company is a mistake, up or down. Norchi's presentation was excellent and the new slides in the presentation added valuable insight.[...]

This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

Connect with Travis

website designed by Gravity Switch